Eli Lilly price target raised to $957 from $925 at Jefferies

Jefferies raised the firm’s price target on Eli Lilly to $957 from $925 and keeps a Buy rating on the shares after the donanemab Advisory Committee documents came out and “look fine.” While the FDA flagged that they didn’t agree with Lilly changing the primary endpoint to iADRS from CDR-SB in TB-ALZ2, they stated that it may be reasonable to generalize donanemab’s efficacy results across the spectrum of tau burden and other than ARIA-related deaths, the FDA concluded deaths weren’t causally related to donanemab, whose overall safety was described as consistent with the class, the analyst tells investors. The FDA panel meeting is set for Monday June 10 at 9 AM ET, the analyst noted.